Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jakavi

- PMLiVE

Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer

Results from the phase 3 trial demonstrated superiority over standard of care Docetaxel chemotherapy in KRAS G12C-mutated non-small cell lung cancer

- PMLiVE

Novartis’ Scemblix receives EC approval for chronic myeloid leukaemia

It is estimated that more than 6,300 people will be diagnosed with CML in Europe every year

- PMLiVE

Novartis to temporarily suspend Huntington’s disease phase 2b study after side effects reported

A data review found that branaplam may cause peripheral neuropathy, which is the result of nerve injury outside the brain and spinal cord

- PMLiVE

New study shows pioneering test for endometrial cancer could significantly reduce diagnosis time

The study findings have been published in the Journal of Clinical Oncology

- PMLiVE

Novartis to separate generic drugs division Sandoz to create standalone company

The spin-off will allow shareholders to participate fully in the potential future upside of both companies

- PMLiVE

Roche launches digital PCR system to identify ultra-rare and emerging disease mutations

The diagnostics platform will allow researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions

- PMLiVE

EC approves Celltrion Healthcare’s Vegzelma for multiple cancer types

The biosimilar to Genentech's Avastin was found to be highly similar to the reference product

- PMLiVE

Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics

The deal offers BMS a pipeline of investigational medicines to expand its oncology portfolio, including repotrectinib

- PMLiVE

Novartis reports death of two patients treated with Zolgensma

The company has notified health authorities in markets where the drug is sold and has informed relevant healthcare professionals

- PMLiVE

Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer

The approval for the treatment applies to England, Scotland and Wales

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

- PMLiVE

Boehringer Ingelheim and QUANTRO Therapeutics partner to develop drug candidates

The collaboration aims to offer a long-term strategy to provide breakthrough cancer treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links